Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
N. Yu. Velts
Observed names:
N. Y. Velts,
N. Yu. Vel’ts
Institution:
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (SCEEMP)
Observed institutions:
Ministry of Health of the Russian Federation,
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (SCEEMP)
ORCID:
0000-0002-9514-6322
Observed ORCID:
0000-0002-9514-6322
OpenAlex ID:
A5046513164
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
2020
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
31
PDF
International Drug Safety Monitoring
2019
·
A. S. Kazakov
, E. V. Shubnikova
, et al.
·
Safety and Risk of Pharmacotherapy
·
30
PDF
Limits for the Content of Heavy Metals and Arsenic as a Means of Ensuring Safe Use of Herbal Medicinal Products
2021
·
M. S. Galenko
, I. V. Gravel
, et al.
·
Safety and Risk of Pharmacotherapy
·
14
PDF
Comparative Analysis of International Databases of Adverse Drug Reactions
2020
·
A. S. Kazakov
, M. A. Darmostukova
, et al.
·
Safety and Risk of Pharmacotherapy
·
12
PDF
Nonsteroidal anti-inflammatory drugs: problems of safe use
2018
·
N. Yu. Velts
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
12
Fluoroquinolone antibiotics: safety of use by the example of ciprofloxacin
2019
·
N. V. Molchan
, Yu. A. Smirnova
, et al.
·
Safety and Risk of Pharmacotherapy
·
10
PDF
Ototoxicity of Aminoglycosides the Modern Concepts
2023
·
E. V. Shubnikova
, N. Yu. Velts
·
Antibiot Khimioter = Antibiotics and Chemotherapy
·
8
PDF
Nanoscale Therapeutic System: Safety Assessment Features
2019
·
E. M. Bovina
, B. K. Romanov
, et al.
·
Safety and Risk of Pharmacotherapy
·
8
PDF
Post-marketing Drug Safety Research: Analysis of Recommendations of Foreign Regulators
2018
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
8
Signal as a Tool of the Pharmacovigilance
2018
·
E. O. Zhuravleva
, N. Yu. Velts
, et al.
·
Safety and Risk of Pharmacotherapy
·
7
The Adverse Drug Reactions Registered During the Postmarketing Period
2019
·
E. V. Shubnikova
, M. A. Darmostukova
, et al.
·
Safety and Risk of Pharmacotherapy
·
6
Expert Evaluation of Pharmacovigilance System Documents Included in the Registration Dossier
2020
·
I. I. Snegireva
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
4
PDF
On the Issue of Safety of Non-steroidal Anti-inflammatory Drugs
2018
·
N. Yu. Velts
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
4
PDF
Methodological Approaches to Risk Management of Advanced Therapy Medicinal Products
2023
·
A. A. Taube
, N. Yu. Velts
·
Drug development & registration
·
3
PDF
Vaccine Safety International Monitoring
2019
·
M. A. Darmostukova
, I. I. Snegireva
, et al.
·
Safety and Risk of Pharmacotherapy
·
3
Pharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice
2023
·
N. Yu. Velts
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
2
PDF
Analysis of Noncompliances with Legislative Requirements in Pharmacovigilance Materials of Registration Dossiers
2021
·
E. O. Zhuravleva
, N. Yu. Velts
, et al.
·
Safety and Risk of Pharmacotherapy
·
2
PDF
Analysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease
2022
·
N. Yu. Velts
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Safety of Antibacterial and Antiprotozoal Medicinal Products
2022
·
E. V. Shubnikova
, T. M. Bukatina
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Drug Safety Monitoring Information
2021
·
E. V. Shubnikova
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Signal Messages in Pediatric Practice
2018
·
G. V. Kutekhova
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
·
1
PDF
Pharmacovigilance in the Geriatric Population: Analysis of Risk Management Plans for Medicinal Products in Russia in 2024
2025
·
N. V. Tereshkina
, N. Yu. Velts
, et al.
·
Safety and Risk of Pharmacotherapy
Adverse Reactions to Intravenous Immunoglobulin Therapy: An Analysis of the Russian National Pharmacovigilance Database
2024
·
A. V. Nechaev
, S. A. Leshina
, et al.
·
Safety and Risk of Pharmacotherapy
PDF
Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors
2024
·
N. Yu. Velts
, E. O. Zhuravleva
, et al.
·
Safety and Risk of Pharmacotherapy
PDF
Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
2024
·
N. Yu. Velts
, O. V. Velts
, et al.
·
Safety and Risk of Pharmacotherapy
Show more works
View as search
Works count:
30
Citation count:
168
H-index:
8
I10-index:
6
Year
Topic
Type